Related Experiment Videos
Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy
1Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract:
We assessed survival in AIDS-related progressive multifocal leukoencephalopathy (PML) and the effect of cytarabine and antiretroviral therapy in a retrospective analysis of a series of consecutive 35 patients with AIDS-related PML in an academic AIDS referral center over 15 years. Treatment regimens consisted of highly active antiretroviral treatment (HAART), intravenous cytarabine, or both. Median survival after diagnosis in the overall series was 88 days. Patients with low CD4 cell count tended to have shorter survival. Seven patients (20%) had prolonged survival (> 1 year). Cytarabine did not affect survival. Seven patients were treated with HAART, which did not significantly improve survival. We conclude that the prognosis of AIDS-related PML is still poor, with a median survival of 3 months.
Insights
Survival for progressive multifocal leukoencephalopathy (PML) in AIDS patients remains poor, with a median survival of 88 days. Neither cytarabine nor highly active antiretroviral treatment (HAART) significantly improved outcomes in this study.
Area of Science:
- Neuroscience
- Immunology
- Infectious Diseases
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal, demyelinating disease of the central nervous system.
- PML is caused by the JC virus (JCV) and predominantly affects individuals with compromised immune systems, particularly those with advanced HIV/AIDS.
- The prognosis for AIDS-related PML has historically been poor, with limited effective treatment options.
Purpose of the Study:
- To evaluate the survival rates of patients diagnosed with AIDS-related progressive multifocal leukoencephalopathy (PML).
- To investigate the impact of cytarabine and highly active antiretroviral treatment (HAART) on survival in this patient cohort.
Main Methods:
- Retrospective analysis of 35 consecutive patients with AIDS-related PML treated at an academic AIDS referral center over 15 years.
- Patient treatment regimens included HAART, intravenous cytarabine, or a combination of both.
- Survival data was collected and analyzed, with attention to factors such as CD4 cell count.
Main Results:
- The median survival after diagnosis for the entire cohort was 88 days (approximately 3 months).
- Patients with lower CD4 cell counts exhibited a trend towards shorter survival.
- Cytarabine treatment did not demonstrate a significant effect on survival.
- Seven patients (20%) experienced prolonged survival exceeding one year.
- The administration of HAART in seven patients did not significantly improve survival rates.
Conclusions:
- The prognosis for AIDS-related PML remains poor, characterized by a short median survival.
- Current treatment strategies, including cytarabine and HAART, have not shown a significant impact on improving survival in this population.
- Further research into novel therapeutic interventions is warranted for AIDS-related PML.